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Abstract
Background: Extended-spectrum β-lactamases producing Escherichia coli (ESBL-E) are increasingly identified in
health care facilities. As previously done for the control of methicillin-resistant Staphylococcus aureus, many hospitals
have established screening strategies for early identification of patients being carriers of ESBL producers in general
and ESBL-E in particular, and have implemented contact precautions (CP) for infected and colonized patients.
Methods: The incidence of ESBL-E has been compared retrospectively between two French university hospitals
(A and B) with different infection control policies over a 5-year long period of time (2006–2010).
Results: While hospital A only implemented standard precautions after identification of patients colonized with
ESBL-E, hospital B recommended additional CP. During the period of the study, the ESBL-E incidence rate
significantly increased in both hospitals, but no significant difference was observed between the two hospitals.
Conclusions: This observational study did not reveal that additional CP measures had a greater impact on the
incidence of ESBL-E in hospital settings.
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Background
Since the early 21th century, extended-spectrum ß-lacta-
mase (ESBL) producing Enterobacteriaceae are spread-
ing worldwide [1]. Those ESBL producers are mainly
Escherichia coli isolates that may be found either in
nosocomial settings but also in the community, and also
Klebsiella pneumoniae and Enterobacter cloacae which
are mainly nosocomial species. In some geographical
areas, the rate of ESBL-producing E. coli is actually
reaching 67 % [2]. Most of the ESBL enzymes are of
CTX-M types, with CTX-M-15 being the most fre-
quently identified variant in particularly in France [3].
The situation in France is endemic and the extensive
spread of some specific clones such as E. coli ST131
have been shown to be a major feature [4]. However
detailed molecular analyses of those ESBL producers
showed some diversity in term of clones, isolates, plas-
mids, and ESBL genes [5]. Considering that the spread
of ESBL-producing E. coli has reached an alarming rate,
defining the most cost-efficient measures to control their
spread in hospital settings represents a major issue.
In order to control and subsequently decrease the
impact of ESBL producers in healthcare settings and
related nosocomial infections, some authors [6] and med-
ical societies actually recommend the implementation of
contact precautions during hospitalization for colonized
and infected patients, similarly to policies applied to
control the spread of methicillin-resistant Staphylococcus
aureus (MRSA).
To our knowledge, the most efficient control policies
in reducing the incidence of ESBL-producing Enterobac-
teriaceae in hospital settings remain to be precisely
determined. Many studies show that screening of ESBL
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producers at admission and implementing contact isola-
tion might be effective for controlling their spread in
hospital settings. However, most of those studies have
been designed to control the spread of ESBL-producing
K. pneumonie [7] or ESBL-producing E. cloacae and
prevent related outbreaks that are quite commonly ob-
served. By contrast, it is well admitted that nosocomial
outbreaks linked to E. coli ESBL producers outbreaks are
basically uncommon [8].
The aim of this study was to compare the incidence of
ESBL-producing Enterobacteriaceae and specifically
ESBL-producing E. coli in two French University hospi-
tals located in the Paris area (Necker-Enfants-Malades
hospital [hospital A] and Bicêtre hospital [hospital B]).
In those two similar hospitals, distinct infection control
policies regarding ESBL-producing E. coli were indeed
implemented, making the comparison meaningful.
Methods
Setting
A retrospective study was conducted between January
1st 2006 and September 30th 2010 into all short-stay
units from the hospitals A to B. Hospital A is a 550-bed
University hospital with around 26,000 direct admissions
per year, a mean hospitalisation stay of 5 days and a
children/adult bed ratio of 4. Hospital B is an 800-bed
University hospital with around 680 acute beds, almost
30,000 direct admissions per year, a mean hospitalisation
stay of 7 days and a children/adult bed ratio of 0.2. In
both hospitals all patients hospitalized in a short-stay
unit were included as soon as a positive clinical sample
growing an ESBL-producing Enterobacteriaceae was
identified. Only the first ESBL-positive isolate was
considered for each patient.
Infection control policies
In both hospitals infection control policies for multidrug-
resistant organisms (MDRO) consisted in active surveil-
lance for patients hospitalized in intensive care units
(rectal swab screening upon admission and weekly follow-
up) and also in passive surveillance of all clinical samples
tested routinely. Some specific measures could also be
added in other hospitalization units in case of epidemic
situations. When a MDRO was isolated (new patient
detection or readmission of a known carrier) and required
implementation of additional care precautions, the infec-
tion control team monitored health workers about the
infection control recommendations (first by phone and
then followed by a physical visit).
In France, the infection control guidelines currently
suggest that, regardless of species, all patients infected
or carriers of any type of ESBL-producing Enterobacteri-
aceae shall be isolated (http://www.sf2h.net/).
Contact isolation requires a private room, patient dedi-
cated medical equipment and a specific signboard on
the door of the patient’s room. Gown wearing is recom-
mended when entering the patient room especially
during a long and close care. Wearing gloves was
mandatory when the health care worker was in contact
with blood or body fluids. Hand hygiene involved hand
rubbing with a waterless alcohol-based hand rub or hand
washing with soap and water. As for standard care pre-
cautions, hand hygiene was recommended before and
after touching the patient or his/her environment and
after wearing gloves, i.e., after contact with blood or
body fluids from the patient.
The hospital A Infection Control Committee decided
to maintain strict contact isolation procedures for
patients infected or colonized with any kind of ESBL
producers, and the implementation and enforcement of
the proposed measures was daily controlled. By contrast,
isolation of patients infected or colonized with ESBL-
producing E. coli was abandoned since 2008 at hos-
pital B, with the exception of patients hospitalized in
the neonatal intensive care unit. Noteworthy, contact
isolation was maintained for all patients found to be
infected or colonized by any other ESBL-producing
Enterobacteriaceae. That decision resulted from the
observation that the hospital was facing out a signifi-
cantly increased incidence of ESBL-producing E. coli.
That unexpected phenomenon which paradoxically
did not result into an increased number of noscoco-
mial outbreaks involving ESBL-producing E. coli in
hospital B, nevertheless resulted in a major additional
workload for the hospital staff. In fact, both hospitals
applied the same infection control policies from 2006
to 2008 but adopted distinct policies during the
2008–2010 period.
Rectal swabs were plated onto selective chromogenic
medium for screening of ESBL-producing Enterobacteria-
ceae (chromID ESBL Agar, bioMérieux, Marcy-l’Etoile,
France). Bacteria were identified at the species level by
standard biochemical-based techniques. Antibiotic suscep-
tibility testing was performed and interpreted according to
the EUCAST guidelines [9]. The double-disk synergy test
was used to detect ESBL-producing Enterobacteriaceae.
Hospital consumption data
Yearly volume of alcohol-based hand rub solution was
defined as the total of volume consumption by hospital
wards and expressed in liters by 1000 days of
hospitalization. Antibiotic consumption was expressed
as Defined Daily Dose according to WHO recommenda-
tion (http://www.whocc.no/atc_ddd_publications/guide
lines/). These data were available from January 1st, 2006
to December 31th, 2009.
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Statistical analyses
Population characteristics were qualitatively described for
each hospital in terms of medical activity, patients’ recruit-
ment and ESBL-producing Enterobacteriaceae. Parametric
(Chi2) or non parametric (Kolmogorov-Smirnov [KS])
tests were computed to quantify the difference between
both hospitals on the basis of major descriptive factors, ie:
age, gender, speciality (type of unit or clinical unit activity),
clinical site and bacterial species.
Quarterly ESBL-producing Enterobacteriaceae inci-
dence was defined as the number of clinical samples
from which at least a single ESBL-producing Enterobac-
teriaceae had been isolated per patient, per 3 months
and by 1000 days of hospitalization. The quarterly inci-
dences were estimated for the main ESBL-producing en-
terobacterial species, namely E. coli, K. pneumoniae and
E. cloacae. Evolution of those incidences were average
plotted to observe trends and outbreaks. The difference
in ESBL-producing E. coli incidence between hospitals A
and B before and after 2008 was evaluated by a match-
pairs T-test where each quarter represented a pair of
data. Therefore, we could compare a difference of mean
for eight quarters before the modification in hygiene
practices in hospital B and a difference of mean for 11
quarters after 2008. Alcohol hand rub and antibiotics
consumptions have been described by the average rate
of increase or decrease of consumption per year between
2006 and 2009. All the statistics were performed using
Excel Microsoft and SAS software (version 9.2, SAS
Institute Inc., Carry, NC, USA).
Results
Hospitals A and B were quite similar in terms of medical
activity. The number of direct admissions per bed and
year were respectively 47 (25, 882/551) in hospital A and
44 (29, 501/678) in hospital B despite a slight difference
in the mean hospitalization stay (6.7 days for hospital B
versus 5.4 days for hospital A).
A total of 499 and 659 clinical samples positive for
ESBL-producing Enterobacteriaceae were included for
hospitals A and B, respectively. As expected, the patients
characteristics showed some significant differences
between hospitals A and B, patients at hospital B being
significantly older than patients at hospital A, median:
61 years-old versus 9 years-old (KS Test, p < 0.0001) but
no significant difference was observed in the gender rate
(Chi2 Test, p = 0.50).
Distribution of unit activity among each hospital
was significantly different (Chi2 Test, p < 0.0001).
More patients were hospitalized in intensive care
units (ICUs) at hospital B whereas the proportions of
patients from the medicine and surgery wards were
quite similar for both hospitals, being respectively
53.4 to 41.1 % for hospital A, and 33.1 to 27.7 % for
hospital B. When excluding patients hospitalized in
ICUs, no significant difference was observed (Chi2
Test, p = 0.54).
Clinical sites associated with an ESBL-producing iso-
late were equally distributed between hospitals A and B
except for the non-protected lower respiratory tract
samples (10.2 % for hospital A versus 3.3 % for hospital
B). The proportion of ESBL-producing K. pneumoniae
was higher in hospital A compared to hospital B, being
37.5 and 27.5 %, respectively (Table 1).
The overall incidence rate of ESBL-producing Entero-
bacteriaceae significantly increased in both hospitals from
January 2006 to September 2010, with a higher increase
observed in hospital A compared to hospital B. These
rates increased from 0.41 to 1.87/1000 patients-days in
hospital A and from 0.54 to 1.31/1000 patients-days at
hospital B.
The evolution of quarterly incidences for ESBL-
producing enterobacterial species differed when con-
sidered the three most prevalent species E. coli, K.
pneumoniae and E. cloacae. Indeed, the rate of ESBL-
producing E. coli increased linearly in both hospitals
where no outbreak episode was observed during the
study period, while the respective rates of ESBL-
producing K. pneumoniae and ESBL-producing E.
cloacae significantly increased and correlated with
several outbreak episodes. In hospital B, four outbreak
episodes occurred, corresponding to two outbreaks of
infections caused by ESBL-producing K. pneumoniae
in 2007 and 2009, and two outbreaks of infections
caused by ESBL-producing E. cloacae in 2009 and
2010. In hospital A, two outbreak episodes occurred,
corresponding to an outbreak of infections caused by
ESBL-producing E. cloacae in 2009 and an outbreak
of infections caused by ESBL-producing K. pneumo-
niae in 2010 (Figs. 1 and 2).
The impact of infection control policies was evaluated
by comparing the respective incidences of ESBL-
producing E coli in the two hospitals. Before 2008, the
means of ESBL-producing E. coli quarterly incidences
were respectively at 0.14/1000 patient-days (confidential
interval [CI], 5 % [0.08–0.21]) in hospital A and 0.20/
1000 patient-days (CI, 5 % [0.14–0.26]) in hospital B.
After 2008, the means of ESBL-producing E. coli quar-
terly incidences were respectively 0.41/1000 patient-days
(CI, 5 % [0.33–0.48]) in hospital A and 0.40/1000
patient-days (CI, 5 % [0.32–0.48]) in hospital B. Using a
matched-paired T-test, the difference between quar-
terly incidences in hospital B minus hospital A
(DeltaI compared to 0) were compared during the
entire study period, but also before and after 2008
when new practices for management of patients
infected or colonized by ESBL-producing E. coli were
implemented in hospital B. When considering the
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entire study period, the DeltaI mean was 0.019/1000
patient-days, p = 0.36; before 2008, it was 0.059/1000
patient-days, p = 0.08; and after 2008, it was –0.009/
1000 patient-days, p = 0.73. Therefore no difference
was observed between the two hospitals in terms of
incidence of ESBL-producing E. coli irrespective of
the period of time (Table 2).
The consumption of alcohol-based hand rubs (AHRs)
and antibiotics was similar during the 2006–2009 period
in both hospitals, with an increase of AHR (+20 %/year
Table 1 Features related to isolation of ESBL-producing Enterobacteriaceae in both hospitals during the Jan 2006 – Sept 2010 period
Features Hospital A Hospital B p
Median age (Q1-Q3), n 9 (2–52), n = 499 61 (45–74), n = 659 <0.0001*
Gender
Men 53.9 %, n = 269 51.9 %, n = 342 0.5
Women
Hospitalization unit (%), n
Medicine 53.4 %, n = 266 41.1 %, n = 271 <0.0001*
Surgery 33.1 %, n = 165 27.7 %, n = 183 without
ICU 13.5 %, n = 67 31.1 %, n = 205 ICU
Clinical site (%), n 0.54**
Urine 60.5 %, n = 302 59.9 %, n = 395 <0.0001*
Blood culture 10.2 %, n = 51 9.1 %, n = 60 without
Respiratory no protected 10.2 %, n = 51 3.3 %, n = 22 respiratory
Respiratory protected 3.8 %, n = 19 4.1 %, n = 27 no protected
Intravascular devices 4.7 %, n = 23 6.4 %, n = 42 0.07**
Deep purulent samples 1.8 %, n = 9 4.1 %, n = 27
Others 8.8 %, n = 44 13.1 %, n = 86
ESBL-producing Enterobacteriaceae by species (%), n
Escherichia coli 38.7 %, n = 193 44.6 %, n = 294 0.0033*
Enterobacter cloacae 15.4 %, n = 77 19.3 %, n = 127 without K. pneumoniae
Klebsiella pneumoniae 37.5 %, n = 187 27.5 %, n = 181 0.73**
Other ESBL producers 8.4 %, n = 42 8.7 %, n = 57
*p < 0.05, or **p > 0.05 after deleting the varying category between hospital; Kolmogorov-Smirnov and Chi2 Test
Fig. 1 Respective quarterly ESBL-producing E. coli incidences in hospitals A and B; January 1st, 2006 to September 30th, 2010
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for hospital A and +28 %/year for hospital B) and a de-
crease of antibiotic consumption (−4 %/year for hospital
A and −3 %/year for hospital B).
Discussion
During this retrospective study performed in two Uni-
versity hospitals in the Paris area, an increased isolation
of ESBL-producing Enterobacteriaceae from infected
sites was observed from 2006 to 2010. The increase was
mainly related to the increased incidence of ESBL-
producing E. coli, which is basically related to its
increased prevalence in the community [10]. However, it
is noteworthy that no entry screening was performed
and therefore the true burden of patients being already
colonized with ESBL-producing E. coli at admission re-
mains unknown in our study. In addition, no molecular
typing was performed here and we cannot completely
assess that ESBL-producing E. coli isolates were trans-
mitted or just brought by the patients. These are two
important features that might be considered in further
studies. Interestingly, despite strict adherence to national
guidelines, isolation policies adopted in the two hospitals
from 2006 to 2008 were not associated with a decreased
incidence of ESBL-producing E coli. Moreover no differ-
ence was observed between the two hospitals despite dis-
continuation of the isolation policy in hospital B after
2008. This result contradicts studies indicating the efficacy
of these measures (together with other interventions) to
control the spread of different resistant bacteria such as
MRSA [11] vancomycin-resistant Enterococci [12] and
ESBL-producing K. pneumoniae [7], and from which is is
believed that CP does prevent cross transmission.
These data suggest that contact isolation procedures
aimed to prevent or to limit the spread of ESBL-
producing E. coli are actually inefficient. This might be
explained by the fact that contact isolation might be
poorly beneficial in a context where health care workers
hand hygiene compliance is either high or very low [13].
Another issue is that contact isolation has almost no role
in preventing endogeneous infections caused by the
patient’s gut flora, which has to be placed into the per-
spective of an increased prevalence of ESBL-positive E.
coli in the community in France [14].
Other hypotheses might explain the lack of efficiency
of contact isolation for controlling the spread of ESBL-
producing E. coli. Indeed, the spread of MDRO depends
on numbers of factors such as colonization pressure (i.e.,
number of patients admitted with MDRO), cross trans-
mission (i.e., adherence to hand hygiene), and selective
pressure (i.e., antibiotic consumption) [15, 16]. Consider-
ing the high rate of ESBL-producing E coli in the com-
munity and the number of risk factors associated with
such carriage, it seems very challenging to identify
patients carrying ESBL-producing E. coli upon admis-
sion. In fact, according to several recent publications
[17], only 15 % of patients colonized with ESBL-
producing E. coli actually develop a clinical infection
related to that organism. Noteworthy, a study performed
with patients with leukemia or haematopoietic stem cell
transplantation could not confirm any association be-
tween colonization and infection with ESBL-producing
E. coli or any increased hospital mortality [18]. There-
fore, limiting isolation policies to infected patients only
might have a limited impact by missing a large propor-
tion of carriers. It is known that infection control mea-
sures implemented to control the spread of MRSA
strains must include infected but also colonized patients
to be efficient [19].
Fig 2 Respective quarterly ESBL-producing K. pneumoniae and E. cloacae incidences in hospitals A and B; January 1st, 2006 to September
30th, 2010
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The increased rate of ESBL-producing E. coli in the
two hospitals could also be explained by a non-effective
antibiotic stewardship, despite adherence to a national
program implemented since 2005 that resulted into a
decrease of antibiotic consumption by 10 % in hospital B
and by 12.5 % in hospital A between 2006 and 2009.
Indeed, several studies have shown the beneficial out-
come of antibiotic usage restriction in decreasing the
incidence of ESBL-producing Enterobacteriaceae [7].
One of the major issue raised by this study is the prob-
lem to evaluate the risk of bacterial spread at the species
level. Analysis of the literature shows that very few noso-
comial outbreaks of ESBL-producing E. coli actually
occur and that those which have been described occur
in special hospital conditions such as neonates or long
term care facilities [20]. Hence most of the hospital-
based outbreaks involving ESBL producers are not
caused by E. coli but by K. pneumoniae. Very few (if
any) data actually exist to assess differential risks
between bacterial species. To our knowledge there is no
study comparing environmental persistence of ESBL-
producing E. coli and ESBL-producing K. pneumoniae or
E. cloacae.
Our study basically has several limitations. First, we
were unable to identify patients carrying ESBL-
producing E. coli at admission and to define the specific
colonization rate in each hospital. However, since both
hospitals are located in the same geographical area, we
may hypothetize that the prevalence of patients colo-
nized by ESBL-producing Enterobacteriaceae at admis-
sion were similar. Then, considering that antibiotic
selective pressure likely plays a role in the spread of
ESBL-producing Enterobacteriaceae in hospitals, one
might argue that the difference of antibiotic consump-
tion could explain our results. Also, it is clear that the
two hospitals do not recruit the same types of patients,
and median ages have been estimated to be significantly
different (61 vs 9 years-old). Hospital A possesses more
pediatric wards than hospital B, therefore one could
argue that the risk of cross transmission in those wards
Table 2 ESBL-producing Enterobacteriaceae, isolated time (IT) by species, and considered variablesa
Median KS test (Q1-Q3), pb
Median IT with 1st and 3rd quartiles
and Kolmogorov-Smirnov (KS) test
ESBL-positive E. coli ESBL-positive E. cloacae ESBL-positive K. pneumoniae
Number of isolates (total = 1078)
Hospital A 1.5 (0–9), n = 186 8.5 (2–23), n = 76 8 (1–23), n = 185
0.13 0.009 0.04
Hospital B 3 (0–13), n = 264 17 (7–31), n = 116 13 (3–28), n = 161
Unit’s activity (n = 1077)
Medicine (reference) 2 (0–8), n = 229 10.5 (2–31), n = 74 8 (1–23), n = 161
Surgery 2.5 (0–14), n = 152 0.30 13 (5–24), n = 54 0.66 7 (1–17), n = 85 0.67
ICU 5 (1.5–13.5), n = 68 0.04 15 (7.5–28.5), n = 64 0.07 17.5 (7.5–37), n = 100 0.003
Age (n = 1058)
Children (<14 y-old) 2.5 (0–9.5), n = 120 7 (1–22), n = 37 8 (2–26.5), n = 136
0.97 0.08 0.61
Adult 2 (0–11), n = 318 14 (6–27), n = 153 11 (1–24), n = 148
Gender (n = 1078)
Men 4 (0–15), n = 199 14 (5–28.5), n = 112 10 (1–24), n = 198
0.09 0.87 0.61
Women 2 (0–8), n = 251 14 (5–27), n = 80 9 (1–25.5), n = 148
Clinical site (n = 961)
Urine (reference) 2 (0–10.5), n = 316 14 (4–28.5), n = 96 8 (1–23), n = 181
Blood culture 2 (0–7), n = 37 0.67 15.5 (5–28), n = 26 0.99 11 (1–28), n = 33 0.41
Respiratory protected 5 (1–14), n = 11 0.94 12 (5.5–24), n = 12 0.63 19 (5–62), n = 19 0.10
Respiratory unprotected 2 (1–7), n = 12 0.96 13 (2–26), n = 14 0.86 8.5 (3–21), n = 38 0.06
Intravascular devices 8 (4–9), n = 7 0.05 14 (7–25), n = 21 0.18 14 (9–21), n = 27 0.006
Deep purulent samples 17 (1–41), n = 17 0.007 18 (4–27), n = 7 0.99 19 (14–21), n = 6 0.19
Total by ESBL producer 2 (0–11), n = 450 14 (5–28), n = 192 10 (1–24), n = 346
aTotal numbers may differ according to categories since some data were not always available; bsignificant level, p < 0.05
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could be higher than in adult wards. We might also
consider that the incidences of ESBL producers are
significantly different.
Finally, since active surveillance at admission was not
implemented except for the ICU, we cannot formally
assess that positive cases were indeed hospital-acquired.
Conclusion
In conclusion, no significant difference between inci-
dences of ESBL-producing E. coli were noted between
the two hospitals, regardless of the different policies of
patient isolation followed. Considering that infection
control activity is costly and time-consuming, and also
that the reservoir of ESBL-producing E. coli is increasing
worldwide, we believe all efforts should focus on all
ESBL-producing Enterobacteriaceae other than E. coli
to prevent nosocomial outbreaks. It is important to
highlight that the findings we actually observed may
not be generalizable to other settings, especially
neonatal wards, neonatal intensive care units, or nurs-
ing homes, where outbreaks of ESBL-producing E.
coli have been described [21–25].
Since nosocomial outbreaks caused by ESBL-producing
K. pneumoniae are frequent, a meaningful strategy would
be to early identify patients being colonized with
ESBL-producing K. pneumoniae, differentiating them
from patients colonized by ESBL-producing E. coli.
Nowadays this can easily be done using selective
chromogenic culture media followed by rapid identifi-
cation of ESBL producers [26].
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